RT Journal Article
SR Electronic
T1 A Survival Score for Patients Assigned to Palliative Radiotherapy for Metastatic Bladder Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1481
OP 1484
VO 37
IS 3
A1 RADES, DIRK
A1 MANIG, LISA
A1 JANSSEN, STEFAN
A1 SCHILD, STEVEN E.
YR 2017
UL http://ar.iiarjournals.org/content/37/3/1481.abstract
AB Aim: To create a survival score for patients with metastatic bladder cancer. Patients and Methods: In 46 irradiated patients, six characteristics were evaluated for their association with survival: Age, gender, Karnofsky performance scale, initial stage (American Joint Committee on Cancer), number of metastatic sites, and interval between bladder cancer diagnosis and palliative radiotherapy. Characteristics showing a trend (p<0.15) were incorporated into the score. Six-month survival rates were divided by 10. Patients' scores were derived by totaling the scores of these characteristics. Results: Performance scale (p=0.14), stage (p=0.055) and number of metastatic sites (p=0.10) showed a trend for association with survival. Patients' scores were 6, 7, 8, 10 or 12 points, with corresponding 6-month survival rates of 20%, 0%, 0%, 46% and 45% (p=0.038). Two groups were created, with 6-8 and with 10-12 points, with 6-month survival rates of 9% and 46% (p=0.002), respectively. Conclusion: A new survival score was developed. Patients with 6-8 points should receive less aggressive treatments for metastatic bladder cancer. Those with 10-12 points may receive more intensive approaches.